Replies to post #120032 on Biotech Values

[jq1234]

With complex proteins that are all a bit different from each other it is a potential concern.

I'd agree it is a potential concern, which is why I mentioned I agreed with the need of physician supervision during switch, at least initially. What I don't agree is it is a BIG conern. To me, BIG concern would prevent interchangeability from happenning at all. Interchangeability should have much higher bar, it seems FDA agrees, and should be looked at case by case basis.